620f38f7-7f22-41f3-a478-445f949006fe
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 64.0848733744011
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.390
- ANGIOGENESIS+0.310
- CHOLESTEROL_HOMEOSTASIS+0.310
- NOTCH_SIGNALING+0.300
- APICAL_JUNCTION+0.290
- WNT_BETA_CATENIN_SIGNALING+0.290
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.220
- MYC_TARGETS_V1+0.220
- MYOGENESIS+0.200
- ESTROGEN_RESPONSE_EARLY+0.190
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.400
- INTERFERON_GAMMA_RESPONSE-0.380
- PROTEIN_SECRETION-0.340
- APICAL_SURFACE-0.280
- ALLOGRAFT_REJECTION-0.230
- ANDROGEN_RESPONSE-0.230
- SPERMATOGENESIS-0.220
- COMPLEMENT-0.210
- APOPTOSIS-0.190
- IL2_STAT5_SIGNALING-0.140
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 701e70ac-31d2-4e78-95e1-3fa2bb466e83 | — | — | 0.787 |
| 2 | R108 | — | — | 0.741 |
| 3 | 06114a88-396c-4815-8949-910e46345e47 | — | — | 0.733 |
| 4 | 82990 | EPN | Supratentorial EPN | 0.715 |
| 5 | DRR168602 | — | — | 0.708 |
| 6 | MNG154 | — | — | 0.694 |
| 7 | BS_C05FKR8X | Supratentorial Ependymoma | — | 0.691 |
| 8 | SRR2016936 | — | — | 0.679 |
| 9 | SRR11296875 | — | — | 0.676 |
| 10 | TCGA-85-6798-01A-11R-1949-07 | — | cohortSQ2 | 0.675 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 25 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.390 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.310 | Remibrutinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.310 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.300 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.290 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.290 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.220 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.220 | Inavolisib | — uncovered |
| MYOGENESIS | 0.200 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.190 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.180 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.140 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.140 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.130 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.100 | Remibrutinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.090 | Remibrutinib | — uncovered |
| UV_RESPONSE_UP | 0.090 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.080 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.070 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.060 | Inavolisib | — uncovered |